Online inquiry

IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3314MR)

This product GTTS-WQ3314MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets lukG&lukH gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq WP_000791407.1; WP_000791411.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 59700810; 59700811
UniProt ID A0A390DBJ6; A0A390DBJ6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ3314MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8147MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ1827MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ6599MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ5621MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ2010MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AGT-181
GTTS-WQ11909MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ2869MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ12258MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MRA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW